OBN and EBD Group Announce BioTrinity's Emergence as the Largest Biotech Partnering Event in the UK

By Obn And Ebd Group, PRNE
Thursday, April 14, 2011

partneringONE(R) Helps Fuel BioTrinity's Growth and Partnering Productivity

OXFORD, England and ZURICH, Switzerland, April 15, 2011 - OBN and EBD Group today announced the results of the fifth annual
BioTrinity Biopartnering and Investment Conference. Held April 12-14 at the
Newbury Racecourse, in Newbury, UK, BioTrinity has grown to become the
largest event of the UK bioindustry with 750 delegates, and has now been
Europe's fastest growing early-stage investment and partnering event for
three years running.

In the past three editions, BioTrinity has more than doubled in size,
from 350 to 750 delegates. The 2011 conference welcomed over 450 companies
from 19 countries across Europe, Asia and North America. The 2011 event also
featured 75 investment firms that specialize in funding emerging
biotechnology companies. partneringONE(R) has been the partnering engine for
BioTrinity over the past five years. During that time, partnering at the
event has grown from 500 one-to-one meetings to 1,700.

"In each of its five years, BioTrinity has achieved that 'magic mix' of
R&D companies, investors and global pharma. Using partneringONE, we are able
to ensure that our mix of attendees is able to identify new business
opportunities and investment, and share sector knowledge," said Jon Rees,
CEO, OBN. "We look forward to working with EBD Group in 2012 and beyond to
continue to provide EBD Group's gold standard partnering services to
BioTrinity participants."

"We are gratified that partneringONE is helping to fuel BioTrinity's fast
growth, creating a strong UK-based event that attracts a growing
international audience," said Carola Schropp, President, EBD Group. "At
BioTrinity, partneringONE is being used by delegates and investors alike to
find and create powerful relationships to drive the industry forward. It is
not only at EBD Group events that partneringONE is contributing to the growth
of the industry."

"The key to a conference's sustained growth is providing attendees with a
high, measurable return on investment. partneringONE helps achieve this by
facilitating meaningful interactions among delegates; interactions that lead
to profitable new business opportunities," Schropp added.

BioTrinity 2011 featured a showcase of the best of the UK's emerging and
clinical stage companies. Big pharma and their corporate venturers
participating in 2011 included Abbott, AstraZeneca, Baxter, Boehringer, Fosun
Pharma, GSK, Lilly, Lundbeckfund, Merck, Merck Serono, Novartis, Novo A/S,
Pfizer, sanofi-aventis, Shire, Smith & Nephew, Takeda, and Teva.

partneringONE is the leading conference partnering service enabling
delegates to efficiently meet and do business. Combining the industry's most
advanced networking software with best practice implementation, partneringONE
turns any conference into a world-class partnering event. As the partnering
engine for over twenty-five clients around the world including six new events
in the past twelve months, partneringONE utilizes the most advanced and
intuitive software for generating connections that matter.

About EBD Group

EBD Group is the leading partnering firm for the global life science
industry. Since 1993, biotech, pharma and medical device companies have
leveraged EBD Group's partnering conferences, technology and services to
identify business opportunities and develop strategic relationships essential
to their success.

EBD Group's conferences are run with the support of leading corporations
and international trade associations, and include:

- BIO-Europe(R) and BIO-Europe Spring(R), Europe's largest life science
partnering conferences, supported by the Biotechnology Industry Organization

- BioPharm America(TM), the fastest growing partnering event in North

- EuroMedtech(TM), EBD Group's partnering event for the innovative
medical technology industry

- BioEquity Europe, the investor conference co-organized with
BioCentury Publications and BIO

- ChinaBio(R) Partnering Forum, the first dedicated biotech/pharma
partnering conference in China, co-produced with ChinaBio(R) LLC

- Biotech Showcase(TM), a unique forum in San Francisco for presenting
to investors and business development executives, co-produced with
Demy-Colton Life Science Advisors

EBD Group's sophisticated web-based partnering service, partneringONE(R),
is used as the partnering engine at numerous third-party events around the
world. Outside of the conference format, EBD Group's consultants provide
hands-on assistance for firms seeking to in- or out-license products and
technologies. EBD Group has offices in the USA and Europe.
For more information visit www.ebdgroup.com

About OBN

OBN is a not-for-profit business network which provides comprehensive
support for its member biotech and medtech companies in the Oxford and
South-East England biocluster and the rest of the UK. Our activities can be
summarised as networking, partnering, group purchasing, advice and
information dissemination. Through its delivery of Europe's fastest growing
biopartnering and investment conference, BioTrinity, OBN generates more
R&D-company-to-investor interactions than anyone else in Europe. OBN is
sponsored by Shire, as Corporate Patron, and Corporate Sponsors MEPC, Manches
LLP, James Cowper, Red Moon Executive Search, PiR Interims, SRG, FOCUS
Insurance, World Courier and Citigate Dewe Rogerson as well as by its
extensive membership of R&D companies and other companies across the entire
life sciences industry ecosystem. OBN counts nearly 200 companies amongst its
membership, which is growing about 45% per year.



    Jon Rees

    EBD Group

    Constantine Theodoropulos
    EBD Group

    Citigate Dewe Rogerson
    Nina Enegren


will not be displayed